O'Shaughnessy Elizabeth M, Shea Yvonne M, Witebsky Frank G
Pediatric Oncology Branch, National Cancer Institute, Building 10, Room 13N-240, 10 Center Drive, Bethesda, MD 20892, USA.
Infect Dis Clin North Am. 2003 Mar;17(1):135-58. doi: 10.1016/s0891-5520(02)00069-7.
Rising numbers of immunocompromised patients have led to an ever-increasing population at risk of invasive fungal disease. Much has been achieved in the laboratory diagnosis of these infections, such as advances in blood culture systems, and the development of new biochemical, antigen detection assays, and molecular methodologies. More standardized susceptibility testing guidelines provide for better therapeutic interventions. In an era of economic cutbacks in health care, future challenges include the development of cost-effective and technically simplified systems, which provide early detection and identification of common and emerging fungal pathogens. It will, however, take some time to establish the clinical relevance of these new methodologies in different patient populations.
免疫功能低下患者数量的不断增加导致侵袭性真菌病的高危人群不断扩大。在这些感染的实验室诊断方面已经取得了很大进展,例如血液培养系统的进步,以及新的生化、抗原检测方法和分子方法的开发。更标准化的药敏试验指南有助于更好的治疗干预。在医疗保健领域经济削减的时代,未来的挑战包括开发具有成本效益且技术上简化的系统,以早期检测和鉴定常见及新出现的真菌病原体。然而,要确定这些新方法在不同患者群体中的临床相关性还需要一些时间。